A phase I dose escalation safety and pharmacokinetic (PK) study of SSR244738 administered as a one-hour intravenous (IV) infusion every 3 weeks in patients (pt) with refractory solid tumors / F.G. De Braud, N.I.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 25:18, suppl.(2007). (43. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago (Illinois) 2007).
A phase I dose escalation safety and pharmacokinetic (PK) study of SSR244738 administered as a one-hour intravenous (IV) infusion every 3 weeks in patients (pt) with refractory solid tumors
G. Curigliano;
2007
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
